We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk made some headlines in London this week, presenting positive data from hemophilia therapeutics trials at the International Society of Thrombosis and Hemostasis Annual Congress. Read More
The FDA and the U.S. Patent and Trademark Office (PTO) will be walking the thin line between preserving patents as an incentive for groundbreaking drug developments and limiting them to allow the emergence of cost-effective generic forms of those drugs. Read More
Bristol Myers Squibb (BMS) has settled with Alembic Pharmaceuticals over allegations that Alembic’s proposed generic drug infringed on its blockbuster blood cancer drug Revlimid (lenalidomide). Read More
The use of continuous manufacturing (CM) technology resulted in applicants getting FDA approval faster when compared to batch manufacturing products, according to an FDA audit published in the International Journal of Pharmaceuticals. Read More
Five Republican senators have called on the Senate Finance Committee to hold hearings on a proposed bill that aims to cap the cost of insulin at $35 a month before it is put before the full chamber for a vote. Read More